文献速递头颈外科

XRCC-1 Arg194Trp多态性预测局部晚期喉癌顺铂放化疗预后

Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation.
PubMed 文献 · Head Neck · 2020-01-30

该前瞻性研究纳入150例接受顺铂为基础放化疗的晚期喉鳞癌患者,按XRCC-1 Arg194Trp基因型分为野生型(C/C)和多态型(C/T或T/T)。多态型患者皮肤和口腔黏膜急性放射性毒性显著更高,治疗反应和PFS呈改善趋势但未达统计学显著。

要点

  • XRCC-1多态型与>2级皮肤和口腔黏膜急性放射性毒性显著相关。
  • 多态型患者治疗反应和PFS呈改善趋势但未达统计学显著。
  • XRCC-1 Arg194Trp或可作为局部晚期喉癌放化疗毒性预测标志。

核心结论

  • XRCC-1多态型患者>2级急性放射性毒性发生率显著更高,治疗反应和PFS呈改善趋势。

研究设计与样本

  • 前瞻性研究纳入150例接受顺铂为基础放化疗的晚期喉鳞状细胞癌患者。
  • 按XRCC-1 Arg194Trp基因型分为野生型(C/C)和多态型(C/T或T/T)。
  • 主要终点为评估急性放射性毒性(ARIT)。

临床怎么用

  • XRCC-1 Arg194Trp基因型检测或有助于识别放化疗毒性高风险患者。
  • 多态型患者需加强急性放射性毒性监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To determine X-ray repair cross-complementing 1 gene (XRCC-1) Arg194Trp polymorphism as bio-predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin-based chemoradiation (CRT). METHODS: A total of 150 patients were enrolled in this prospective study. XRCC-1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiation-induced toxicity (ARIT). RESULTS: A significant correlation of skin (P- .04) and oral mucosal ARIT (P- .01) was noticed in the XRCC-1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P- .08). With 33 months of median follow-up, 2-year progression-free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P- .066) and 50.6% vs 62.2% (P- .12). CONCLUSION: XRCC-1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Raturi V, Hojo H, Bhatt MLB, et al. Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head Neck. 2020. PMID: 31997432. doi:10.1002/hed.26083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。